Frontier IP Group PLC (AIM:FIPP) has announced it owns a 4.26% stake in DiaGen Ai Inc, a Canadian firm focused on AI-driven protein and peptide design for medical applications.
It was given the shareholding in return for advisory services provided to DiaGen, originally known as Proteic Bioscience Inc.
Additionally, DiaGen has entered a technology evaluation agreement with The Vaccine Group, a portfolio company of Frontier IP.
This collaboration aims to develop advanced, broadly-protective animal vaccines targeting diseases caused by rapidly mutating viruses, combining their respective expertise in vaccine and AI-driven protein design.
"We have been working with DiaGen for some time," said Frontier CEO Neil Crabb.
"The technology evaluation agreement with TVG demonstrates the benefits of our clusters approach, where expertise and know-how can be shared profitably between companies. I look forward to seeing the successful results of this collaboration."